Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Tvardi Therapeutics ( (TVRD) ).
On October 13, 2025, Tvardi Therapeutics provided an update on preliminary data from its Phase 2 REVERT trial for idiopathic pulmonary fibrosis (IPF), revealing that the study did not meet its goals. Despite the trial’s randomized, double-blind, placebo-controlled design, no significant differences in lung function improvement were observed between the treatment and placebo groups, with high discontinuation rates due to gastrointestinal adverse events. Tvardi plans further analysis to understand these results and continues to develop its next-generation STAT3 inhibitor, TTI-109, with preliminary data expected in 2026.
The most recent analyst rating on (TVRD) stock is a Hold with a $61.00 price target. To see the full list of analyst forecasts on Tvardi Therapeutics stock, see the TVRD Stock Forecast page.
Spark’s Take on TVRD Stock
According to Spark, TipRanks’ AI Analyst, TVRD is a Neutral.
The overall stock score reflects significant financial challenges and a negative valuation outlook, partially offset by positive technical trends and promising corporate developments in clinical trials. The financial performance is the most significant factor, weighing heavily on the score, while the potential for future growth from clinical advancements provides some optimism.
To see Spark’s full report on TVRD stock, click here.
More about Tvardi Therapeutics
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. The company is engaged in clinical trials with TTI-101 in hepatocellular carcinoma and TTI-109 in healthy volunteers.
Average Trading Volume: 142,045
Technical Sentiment Signal: Strong Sell
Current Market Cap: $390.1M
Learn more about TVRD stock on TipRanks’ Stock Analysis page.